Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes

被引:33
作者
Guadagnino, Vincenzo
Trotta, Maria Paola
Montesano, Franco
Babudieri, Sergio
Caroleo, Benedetto
Armignacco, Orlando
Carioti, Jessica
Maio, Giuseppe
Monarca, Roberto
Antinori, Andrea
机构
[1] Magna Graecia Univ Catanzaro, Chair Infect Dis, Postgrad Sch Infect Dis, I-88100 Catanzaro, Italy
[2] IRCCS, Natl Inst Infect Dis Lazzaro Spallanzani, Rome, Italy
[3] UO DDU, Soverato, Italy
[4] Infect Dis Unit AO Viterbo, Viterbo, Italy
[5] Univ Sassari, Inst Infect Dis, I-07100 Sassari, Italy
关键词
HCV infection; intravenous drug use; management of hepatitis C; Peg interferon; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; MAINTENANCE TREATMENT; VIRUS-INFECTION; USERS; THERAPY; CARE; DEPRESSION; BARRIERS;
D O I
10.1111/j.1360-0443.2006.01698.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
Aim To evaluate the effect of a multi-disciplinary standardized management model on the efficacy of pegylated (Peg)-interferon alpha-2b plus ribavirin treatment of chronic hepatitis C in drug addicts undergoing substitutive or antagonist therapy. Design Observational prospective multi-centre study. Setting Six clinical infectious disease centres in collaboration with 11 drug dependency units (DDU) in five Italian regions. Participants Intravenous drug users affected by chronic hepatitis C engaged in detoxification programmes. Methods Application of a multi-disciplinary standardized management model for HCV treatment involving DDU operators, psychologists or psychiatrists and infectious disease specialists. Measurements Very early, early, end-of-treatment and sustained virological response to Peg-interferon alpha-2b plus ribavirin. Findings Fifty-three subjects were studied [43.4% with hepatitis C virus ( HCV) genotypes 1 or 4]. Intent-to-treat analysis showed an end-of-treatment virological response in 58.5% of patients (39.1% genotypes 1 or 4; 73.4% genotype 3) and a sustained virological response in 54.7% (34.8% genotypes 1 or 4; 70.0% genotype 3). There were 19 (35.8%) dropouts and three (5.7%) non-responders: one genotype 1 and two genotype 4. Two (3.8%) patients relapsed: genotypes 1 and 3. On-treatment analysis showed negative HCV-RNA in 40 (93.1%) of 43 subjects who completed the first 12 treatment weeks and in 35 who completed the first 24 treatment weeks. All subjects with an end-of-treatment response, except one with genotype 3 infection, had a sustained response. Conclusions Our data show that antiviral treatment in the context of amulti-disciplinary standardized management model helps many HCV-positive drug addicts achieve a good virological response.
引用
收藏
页码:423 / 431
页数:9
相关论文
共 38 条
[2]
[Anonymous], 1999, J Hepatol, V30, P956
[3]
Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment [J].
Backmund, M ;
Reimer, J ;
Meyer, K ;
Gerlach, JT ;
Zachoval, R .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S330-S335
[4]
Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[5]
Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C [J].
Broers, B ;
Helbling, B ;
François, A ;
Schmid, P ;
Chuard, C ;
Hadengue, A ;
Negro, F .
JOURNAL OF HEPATOLOGY, 2005, 42 (03) :323-328
[6]
Limited success of HCV antiviral therapy in United States veterans [J].
Cawthorne, CH ;
Rudat, KR ;
Burton, MS ;
Brown, KE ;
Luxon, BA ;
Janney, CG ;
Fimmel, CJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01) :149-155
[7]
Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D) [J].
Clark, CH ;
Mahoney, JS ;
Clark, DJ ;
Eriksen, LR .
JOURNAL OF ADVANCED NURSING, 2002, 40 (03) :361-369
[8]
Prevention and treatment of hepatitis C in injection drug users [J].
Edlin, BR .
HEPATOLOGY, 2002, 36 (05) :S210-S219
[9]
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? [J].
Edlin, BR ;
Seal, KH ;
Lorvick, J ;
Kral, AH ;
Ciccarone, DH ;
Moore, LD ;
Lo, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :211-214
[10]
*EMCDDA, 2001, IT DRUG SIT